| Autor: |
Pacot, Laurence, Pelletier, Valerie, Chansavang, Albain, Briand-Suleau, Audrey, Burin des Roziers, Cyril, Coustier, Audrey, Maillard, Theodora, Vaucouleur, Nicolas, Orhant, Lucie, Barbance, Cécile, Lermine, Alban, Hamzaoui, Nadim, Hadjadj, Djihad, Laurendeau, Ingrid, El Khattabi, Laïla, Nectoux, Juliette, Vidaud, Michel, Parfait, Béatrice, Dollfus, Hélène, Pasmant, Eric |
| Předmět: |
|
| Zdroj: |
Human Genetics; Jan2023, Vol. 142 Issue 1, p1-9, 9p |
| Abstrakt: |
Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance but highly variable expressivity. In most patients, Next Generation Sequencing (NGS) technologies allow the identification of a loss-of-function pathogenic variant in the NF1 gene, a negative regulator of the RAS-MAPK pathway. We describe the 5-year diagnosis wandering of a patient with a clear NF1 clinical diagnosis, but no molecular diagnosis using standard molecular technologies. The patient presented with a typical NF1 phenotype but NF1 targeted NGS, NF1 transcript analysis, MLPA, and array comparative genomic hybridization failed to reveal a genetic aberration. After 5 years of unsuccessful investigations, trio WGS finally identified a de novo mosaic (VAF ~ 14%) 24.6 kb germline deletion encompassing the promoter and first exon of NF1. This case report illustrates the relevance of WGS to detect structural variants including copy number variants that would be missed by alternative approaches. The identification of the causal pathogenic variant allowed a tailored genetic counseling with a targeted non-invasive prenatal diagnosis by detecting the deletion in plasmatic cell-free DNA from the proband's pregnant partner. This report clearly highlights the need to make WGS a clinically accessible test, offering a tremendous opportunity to identify a molecular diagnosis for otherwise unsolved cases. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink